<analysis>
**Action 1: bundled 13 January release.** Anthropic has slipped six times, and the base rate is dismal. What's different now: the leak has already made the "uninformative" line public, the CEO owns a date, and securities counsel asked for exactly this bundle in December. Other blockers could still appear:
- The General Counsel's post-leak consistency review may run long.
- The Monterrey paragraphs in the DOJ letter could need more revisions.
- Hawley's records demand could make counsel wary of publishing anything he could subpoena against.
- The board still won't own the date.

The specific risk that the Q4 blackout pushes items toward the 10-K is Threat 1, so I don't count it here. The action's own risk is that none or only one item ships through ordinary counsel and CEO hesitation.

**Action 2: 20 January methodology review.** Bringing finished proposals is better than bringing requests. Still, the evaluation leads have deferred these items twice on principle: you can't calibrate against checkpoints that don't exist yet, and changing methods breaks comparability with the gate. The anomaly-detection spec depends on Action 3's result. Execution risk is that the proposals aren't ready or the researchers get pulled onto the next-generation harness again, as happened in October and November. Institutional rejection of two or more additions is Threat 3, so I keep the two separate.

**Action 3: held-out validation.** It needs two unexposed researchers plus the two engineers, whose serving slot was a holiday windfall. The deadline of 18 January is tight: design the scenarios, run them, analyse. Execution risk is not finishing in time or losing staff. Whether the detector clears 40% recall is a substantive technical outcome, and that is Threat 2. Detectors tuned on three positives usually degrade a lot under distribution shift.

**Action 4: RAISE.** This is routine operations with modest ambition. The final number likely lands around 1,400–1,600, and the cohorts start as scheduled. Low risk.

**Action 5: UK AISI scheduling.** Sending the request is trivial. The action's own failure mode is internal: leadership or legal hesitate to commit a date, or insist on conditions like no checkpoint access. Whether AISI can offer a late-February or early-March slot is Threat 4. AISI capacity is really constrained, and it prefers access-based testing.

**Threats.**
- **Threat 1 (blackout):** plausible. The 10-K risk-factor argument is real for a first annual filing. But quiet periods normally restrict financial statements, not research, and the leak reduces how material the content is.
- **Threat 3:** partly overlaps with Action 2, so I discount it.
- **Threat 5 (DeepSeek V5):** has been "imminent" for more than a year with no release. Lunar New Year 2028 falls on 26 January, so the precedent is real, but a release in one specific week is low odds.

**Capability clock.** The next-generation pretraining run finishes in late January. Early internal numbers should show a visible step toward CI-4, around 4.0–4.05. The formal step lands with the February–March evaluations. That leaves a gap of about 2.0 CI over 35 months, roughly 0.057 per month, so the pace has to hold.
</analysis>

<action_odds>
Action 1 [Bundled Jan 13 release]: P(failure) 40%. Reason: Six prior slips and a post-leak GC review, but the bundle matches counsel's own December ask, the leak removes the novelty risk, and the CEO owns the date. The blackout-specific partial is modelled separately in Threat 1.

Action 2 [Win Jan 20 methodology review]: P(failure) 35%. Reason: Researchers have been pulled onto harness work before, proposal (c) depends on Action 3's results, and the chief scientist deferred these items once already. Principled rejection of two or more additions is handled by Threat 3.

Action 3 [Held-out prototype test]: P(failure) 30%. Reason: Tight 18 January deadline, the engineers' serving slot was a holiday windfall, and staff reclaims have recurred. The detection-rate outcome itself sits in Threat 2.

Action 4 [RAISE enrolment and cohort start]: P(failure) 15%. Reason: Routine operations with modest goals; the main risk is logistics at the new partners.

Action 5 [Schedule UK AISI review]: P(failure) 20%. Reason: Sending the request is easy; the risk is internal hesitation over conditions and checkpoint access. AISI's capacity is modelled in Threat 4.
</action_odds>

<threat_odds>
Threat 1 [Earnings blackout splits bundle]: P(materialises) 33%. Adversary suggested 40%. I'm lower because quiet periods mainly restrict financial disclosures, and the leak already made the key line public, which weakens the materiality argument. The first-10-K risk-factor concern is real, so it stays substantial.

Threat 2 [Held-out test collapses]: P(materialises) 45%. Adversary suggested 50%. It's close because recall collapse under distribution shift is common with detectors tuned on three positives. I remove the staffing route, which is already in Action 3's P(failure), to avoid double-counting.

Threat 3 [Methodology additions rejected]: P(materialises) 30%. Adversary suggested 45%. I'm lower because it overlaps with Action 2's execution risk, finished proposals improve the odds, and outcome-based metrics plus possibly one addition were already on the table.

Threat 4 [AISI can't meet timeline]: P(materialises) 40%. Adversary suggested 45%. AISI's capacity constraint and its preference for access-based testing are real. Its reciprocity relationship and interest in reviewing lab process slightly offset them.

Threat 5 [DeepSeek V5 pre-Lunar New Year drop]: P(materialises) 18%. Adversary suggested 25%. The Lunar New Year precedent is real, but V5 has been "imminent" for more than a year without shipping, and the threat requires release in one specific window.
</threat_odds>
